Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation | Zendy

Alma B Pedersen | Zendy; Uffe HeideJørgensen | Zendy; Henrik Toft Sørensen | Zendy; Daniel PrietoAlhambra | Zendy; Véra Ehrenstein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation

Author(s) -

Alma B Pedersen,

Uffe HeideJørgensen,

Henrik Toft Sørensen,

Daniel PrietoAlhambra,

Véra Ehrenstein

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.2416

Subject(s) - denosumab , medicine , hazard ratio , cohort , bone mineral , osteoporosis , cohort study , population , proportional hazards model , confidence interval , environmental health

Key Points Question What is the real-world risk of fracture for patients treated with denosumab compared with those treated with alendronate? Findings In this Danish cohort study including 4624 individuals treated with denosumab and 87 731 individuals treated with alendronate, 3-year cumulative incidence of hip fracture was 3.7% and 3.1% among the denosumab and alendronate cohorts, respectively. The 3-year cumulative incidence of any fracture was 9.0% for both cohorts. Meaning In routine clinical practice, initiation of denosumab and alendronate treatments were associated with similar risks of hip and any fracture over a 3-year period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research